A subscription to JoVE is required to view this content. Sign in or start your free trial.
Method Article
Here, we describe a simple protocol for the isolation and staining of murine bone marrow cells to phenotype hemopoietic stem and progenitor cells along with the supporting niche endothelial and mesenchymal stem cells. A method to enrich cells located in endosteal and central bone marrow areas is also included.
The bone marrow (BM) is the soft tissue found within bones where hematopoiesis, the process by which new blood cells are generated, primarily occurs. As such, it contains hematopoietic stem and progenitor cells (HSPCs), as well as supporting stromal cells that contribute to the maintenance and regulation of HSPCs. Hematological and other BM disorders disrupt hematopoiesis by affecting hematopoietic cells directly and/or through the alteration of the BM niche. Here, we describe a method to study hematopoiesis in health and malignancy through the phenotypic analysis of murine BM HSPCs and stromal niche populations by flow cytometry. Our method details the required steps to enrich BM cells in endosteal and central BM fractions, as well as the appropriate gating strategies to identify the two key niche cell types involved in HSPC regulation, endothelial cells and mesenchymal stem cells. The phenotypic analysis proposed here may be combined with mouse mutants, disease models, and functional assays to characterize the HSPC compartment and its niche.
Flow cytometry is an invaluable method to characterize and prospectively isolate immune and hematopoietic cells. It is also increasingly being used to analyze stromal and epithelial populations of different tissues. The hematopoietic stem cell (HSC) has unique properties of self-renewal and multipotency. In adult mammals, HSCs primarily reside in the bone marrow (BM), where they receive quiescence and survival signals from the surrounding microenvironment or niche1. HSCs are formally defined according to functional assays2. Nevertheless, several landmark papers have shown the usefulness of flow cytometry to identify HSCs. Through the use of limited cell surface markers, it is possible to discriminate hematopoietic populations that are highly enriched in HSCs3. Flow cytometry is, therefore, a central method in the stem cell field. It has been extensively used to evaluate the impact of putative niche cell types and niche factors on HSCs. By combining flow cytometry with imaging and functional assays, it has been shown that HSCs are critically supported by perivascular mesenchymal stem cells (MSCs) and endothelial cells (ECs). BM MSCs are a heterogenous group and have different cytokine contributions4, but it is well established that leptin receptor (LepR)+ MSCs are key niche cells1. BM ECs are also highly heterogeneous and can be part of sinusoids, arterioles, and type H/transitional vessels5. Different studies have shown the nuanced contribution of these different ECs. For example, endosteal sinusoidal ECs are spatially closer to quiescent HSCs6, while non-migratory HSCs with lower levels of reactive oxygen species are located near arteriolar ECs7. The endosteal versus central location of niches is also very important. Endosteal type H vessels are associated with perivascular stromal cells that are lost with aging, leading to the loss of HSCs8. In acute myeloid leukemia, central ECs are expanded, while endosteal vessels and endosteal HSCs are lost9.
Most studies in the field have focused on hematopoiesis itself and on the cell's extrinsic regulation of HSCs. It has been, however, increasingly recognized that there is a need to better characterize the niches that regulate other progenitors, namely multipotent progenitors (MPPs), particularly considering that they are the main drivers of hematopoiesis in steady state10. In contrast with a fixed hierarchical structure, recent studies have shown that hematopoiesis is a continuum in which HSCs differentiate into biased MPPs at an early stage11. MPPs have been named after different classification schemes12, but a recent consensus paper by the international society for experimental hematology (ISEH) proposed MPPs to be discriminated as early MPPs and according to their lymphoid (MPP-Ly), megakaryocytic and erythroid (MPP-Mk/E), and myeloid (MPP-G/M) bias13. The use of flow cytometry will be critical in further studying the importance of BM niches in the regulation of these populations. Current flow cytometry methods use variable gating strategies to differentiate HSPCs and identify stromal cells, namely ECs, using inconsistent markers. The goal of the current method is to present a simple and reproducible workflow of BM staining to identify HSPC subpopulations, heterogeneous groups of ECs, and LepR+ MSCs. We believe this technique, although comparable with previously reported methods (see, for example, reference14), provides an updated and easy-to-implement protocol for the phenotypic analysis of hematopoietic cells in the two functional marrow areas, endosteal and central BM8,15, as well as BM stromal niche cells.
The animals used in this protocol were housed at the i3S animal facility under specific pathogen-free conditions in a 12 h light-dark cycle and temperature-controlled environment. Free access to standard rodent chow and water was provided. All the animals received humane care according to the criteria outlined by the Federation of European Laboratory Animal Science Associations for the care and handling of laboratory animals (EU Directive 2010/63/EU). The experimental procedure performed on the animals (euthanasia) was approved by the i3S Animal Ethics Committee (ref. DD_2019_15) and the Direção-Geral de Alimentação e Veterinária. Details of the materials used throughout this protocol can be found in the Table of Materials.
1. Preparation of solutions and staining cocktails
2. Sample extraction
3. Sample processing for analysis of hematopoietic cell populations in total bone marrow
4. Sample processing for the analysis of stromal cell populations in total bone marrow
5. Sample processing for the analysis of hematopoietic cell populations in crushed and flushed BM
6. Preparation of single-color controls (SCCs) for flow cytometry analysis
Representative plots of flow cytometry analysis of HSCs and MPPs in a healthy young adult C57Bl/6 mouse are shown in Figure 1. The gating strategy follows the latest harmonizing nomenclature proposed by the ISEH13. When analyzing the impact of a perturbation, such as infection or cancer, it is important to use a control mouse as a reference for normal gates. Fluorescence-minus-one (FMO) controls can be particularly useful to delineate the boundaries of the gates, but ...
While the protocol described is simple and easy to perform, special attention should be brought to specific steps. For example, when obtaining flushed BM (step 5.2), the volume or number of times indicated to pass PBS 2% FBS through the inside of the central part of the bone should not be exceeded, as this might result in significant contamination of the flushed sample by endosteal cell populations.
Alterations to the protocol can be made to facilitate its execution by the investigator. In sam...
The authors have no conflicts of interest to disclose.
LM was supported by a grant from the Lady Tata Memorial Trust. JR was supported by a PhD fellowship from Fundação para a Ciência e Tecnologia (FCT; FCT fellowship UI/BD/150833/2021). ML was supported by a PhD fellowship from FCT (FCT fellowship 2021.04773.BD). DD was supported by grants from the American Society of Hematology, the Pablove Foundation, FCT (EXPL/MED-ONC/0522/2021), and the Portuguese Society of Hematology. We thank the support from Dr. Catarina Meireles and Emilia Cardoso of TRACY facility at i3s.
Name | Company | Catalog Number | Comments |
Alexa Fluor 647 anti-mouse CD54/ICAM-1 antibody | BioLegend | 116114 | |
APC Streptavidin | BioLegend | 405207 | |
APC/Cyanine7 anti-mouse CD117 (c-kit) antibody | BioLegend | 105826 | |
APC/Cyanine7 anti-mouse CD45 antibody | BioLegend | 103116 | |
APC/Cyanine7 anti-mouse TER-119/erythroid cells antibody | BioLegend | 116223 | |
Biotin anti-mouse CD3ε antibody | BioLegend | 100304 | |
Biotin anti-mouse CD4 antibody | BioLegend | 100404 | |
Biotin anti-mouse CD8a antibody | BioLegend | 100704 | |
Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) antibody | BioLegend | 108404 | |
Biotin anti-mouse TER-119/erythroid cells antibody | BioLegend | 116204 | |
Biotin anti-mouse/human CD11b antibody | BioLegend | 101204 | |
Biotin anti-mouse/human CD45R/B220 antibody | BioLegend | 103204 | |
Brilliant Violet 510 anti-mouse CD150 (SLAM) antibody | BioLegend | 115929 | |
Calibrite 2 Color Beads | BD Biosciences | 349502 | |
Collagenase IV | Merck Life Science | C1889 | |
Dispase II | Merck Life Science | D4693 | |
Fetal Bovine Serum, qualified, heat inactivated, E.U.-approved, South America Origin | ThermoFisher Scientific | 10500064 | |
Hanks' Balanced Salt Solution (HBSS) | ThermoFisher Scientific | 14175095 | |
Mouse Leptin R Biotinylated Antibody | R&D systems | BAF497 | |
NucBlue Fixed Cell Reagent (DAPI) | ThermoFisher Scientific | R37606 | DAPI reagent |
PE anti-mouse endomucin antibody | ThermoFisher Scientific | 12-5851-82 | |
PE anti-mouse Flk2 (CD135) | ThermoFisher Scientific | 12-1351-82 | |
PE/Cyanine7 anti-mouse CD31 antibody | BioLegend | 102524 | |
PE/Cyanine7 anti-mouse CD48 antibody | BioLegend | 103424 | |
PerCP anti-mouse Ly-6A/E (Sca-1) antibody | BioLegend | 108122 | |
Phosphate-buffered saline (PBS) tablets | Merck Life Science | P4417 | |
Purified anti-mouse CD16/32 antibody | BioLegend | 101302 | |
RBC lysis buffer 10x | BioLegend | 420302 | |
Zombie Violet Fixable Viability Dye | BioLegend | 423114 | fluorescent dye |
Request permission to reuse the text or figures of this JoVE article
Request PermissionThis article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved